Severe dyspnoea in a patient with chronic myelogenous leukaemia on a tyrosine kinase inhibitor

Pleural adverse drugs reactions and protein kinase inhibitors: Identification of suspicious targets by disproportionality analysis from VigiBase

“…These results demonstrate some discordance with data in the literature regarding the potential for the PD induction by PKIs. Indeed, data have been found for dasatinib [17][18][19][20][21][22][23][24], imatinib [4,[25][26][27][28], erlotinib [29], nilotinib [30,31], sunitinib [32] and bosutinib [33], occurrence of PD is mentioned in only seven summary product characteristics among the 33 PKIs of our study that included bosutinib, dasatinib, imatinib, midostaurin, nilotinib, ponatinib and sunitinib. However, PKIs ranking with the highest RORs were those with data listed in literature, expect for ibrutinib, afatinib and alectinib, which were ranked fourth, seventh and eighth, respectively, for which no data were found.…”

Dasatinib‐induced pulmonary arterial hypertension

“… presented the first case report of PAH confirmed only with TTE in a patient treated with nilotinib for CML, and found that pulmonary pressure decreased after discontinuation of the drug. Moreover, Ustun and colleagues recently presented a case of recurrent PE after the use of both dasatinib and nilotinib. These authors discuss the dilemma about whether the PE was related to the delayed recurrence of the dasatinib‐induced effect, even though, the drug was discontinued, or to a rare AE of nilotinib that started after dasatinib cessation.…”